



**CNIO Frontiers Meetings**  
**Molecular Cancer Therapeutics**  
Madrid, March 8-10, 2010

**Organisers**

**S. Gail Eckhardt**, University of Colorado Denver, Aurora, USA  
**Roy S. Herbst**, The University of Texas MD Anderson Cancer Center, Houston, USA  
**Manuel Hidalgo**, CNIO, Madrid, Spain

**MONDAY, MARCH 8<sup>th</sup>**

9:00-9:15 **Welcome address**  
  
Manuel Hidalgo, CNIO, Madrid, Spain

**Session I: Emerging new cancer targets and drugs**

Chair: Roy S. Herbst

9:15-9:50 **Douglas Yee**, University of Minnesota, Minneapolis, USA  
*"Targeting the insulin-like growth factor receptor as a new cancer therapy"*

9:50-10:25 **Alex Adjei**, Roswell Park Cancer Institute, Buffalo, USA  
*"Targeting the Ras/Raf/MEK pathway for Cancer Therapy"*

10:25-11:00 **Patricia LoRusso**, The Barbara Ann Karmanos Cancer Institute, Detroit, USA  
*"cMET as a Target for Cancer Therapeutics"*

11:00-11:40 *Coffee break*

11:40-12:15 **Josep Tabernero**, Vall d'Hebron University Hospital, Barcelona, Spain  
*"Inhibitors of the PI3K pathway"*

12:15-12:50 **Adrian Senderowicz**, AstraZeneca, Philadelphia, USA  
*"Development of JAK inhibitors for the treatment of human neoplasms"*

12:50-14:20 *Lunch*

**Session II: Lessons learned from recent successfully developed new agents**

**Chair: Alex Adjei**

14:20-14:55 **Jaap Verweij**, Erasmus University Medical Center, Rotterdam, The Netherlands  
***“Clinical development of imatinib mesylate in GIST: Understanding the target”***

14:55-15:30 **Gary Clark**, Array Biopharma, Boulder, USA  
***“Erlotinib: Strategies for a successful clinical development”***

15:30-16:05 **Eric Rowinsky**, New York University School of Medicine, New York, USA  
***“Cetuximab in colorectal cancer: Lessons learned about the development of enrichment biomarkers to maximize the therapeutic index of cancer therapeutics”***

16:05-16:40 **Manuel Hidalgo**, CNIO, Madrid, Spain  
***“Clinical development of mTOR inhibitors in cancer treatment”***

16:40-17:10 *Coffee break*

17:10-18:00 **Key note address**  
**Chair: S. Gail Eckhardt**

**Neal Rosen**, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA  
***“Targeting oncogene addition”***

TUESDAY, MARCH 9<sup>th</sup>

**Session III: Innovation in clinical trials design**

**Chair: Josep Tabernero**

- 8:50-9:25      **Elizabeth Garrett-Mayer**, Medical University of South Carolina, Charleston, USA  
*“Novel trial designs for early phase drug development”*
- 9:25-10:00    **Lillian Siu**, Ontario Cancer Institute, Toronto, Canada  
*“Using phase II trials to fulfill their “Go-No-Go” role”*
- 10:00-10:35   **Emiliano Calvo**, Centro Oncológico Clara Campal, Madrid, Spain  
*“Strategies to combine molecular targeted agents in the clinic”*
- 10:35-11:10   **Lajos Puztai**, University of Texas MD Anderson Cancer Center, Houston, USA  
*“Clinical trial design to prospectively test molecular markers and patient selection strategies”*
- 11:10-11:40   *Group picture and coffee break*

**Session IV: Emerging new anticancer agents**

**Chair: Lillian Siu**

- 11:40-12:15   **Charles Rudin**, The Johns Hopkins University, Baltimore, USA  
*“Targeting the Hedgehog Pathway in Cancer”*
- 12:15-12:50   **Johann de Bono**, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK  
*“Biomarker driven early anticancer drug development”*
- 12:50-13:25   **S. Gail Eckhardt**, University of Colorado Denver, Aurora, USA  
*“PAK4, a novel anticancer target”*
- 13:25-15:00   *Lunch*

**Session V: Short talks from selected abstracts**

**Chair: Elizabeth Garrett-Mayer**

- 15:00-15:20   **Short talk: Magdalena B. Wozniak**, CNIO, Madrid, Spain  
*“Synergistic effects of histone deacetylase and PI3K inhibitors in cutaneous T-cell lymphoma”*
- 15:20-15:40   **Short talk: Cristina Gomez-Abad**, CNIO, Madrid, Spain  
*“PIM as a rational target for B-Cell lymphomas”*
- 15:40-16:00   **Short talk: Miguel Quintela-Fandino**, CNIO, Madrid, Spain  
*“Individual optimal biologic dose titration of sorafenib based on a pharmacodynamic test”*

- 16:00-16:20 **Short talk:** Christopher Heeschen, CNIO, Madrid, Spain  
*"Inhibition of ATR function abrogates in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of CD133+ tumor-initiating cells"*
- 16:20-16:40 **Short talk:** Magdalena Zajac, CNIO, Madrid, Spain  
*"Hsp70 as a biomarker of response and prognostic marker to Hsp90 inhibitor, 17AAG, in breast tumors"*
- 16:40-17:00 **Short talk:** Jordi Rodon, Vall d'Hebron - Institute of Oncology, Barcelona, Spain  
*"Selecting patients for a Phase I trial in the era of targeted therapies"*
- 17:00-17:30 *Coffee break*
- 17:30-18:20 **Key note address**  
**Chair: Manuel Hidalgo**
- Dan Von Hoff**, Translational Genomics Research Institute, Phoenix, USA  
*"Sequencing for 6000!"*

WEDNESDAY, MARCH 10<sup>th</sup>

**Session VI: Applying biomarkers to clinical cancer research**

**Chair: Emiliano Calvo**

- 9:10-9:45      **Richard Wahl**, The Johns Hopkins PET Center, Baltimore, USA  
*“Functional imaging in drug development”*
- 09:45-10:20    **Antonio Jimeno**, The University of Colorado at Denver, Aurora, USA  
*“Pharmacodynamic testing: New directions”*
- 10:20-10:55    **Roy S. Herbst**, The University of Texas MD Anderson Cancer Center, Houston, USA  
*“Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program”*

**10:55 Closing remarks**

**Roy S. Herbst**, The University of Texas MD Anderson Cancer Center, Houston, USA  
**S. Gail Eckhardt**, The University of Colorado at Denver, Aurora, USA

**Note:** Talks: 25 minutes / Short talk: 15 minutes / Key note: 40 minutes

**Discussion:** 10 minutes after each talk / 5 minutes after each short talk / 10 minutes after each key note